Browse > Article
http://dx.doi.org/10.24304/kjcp.2021.31.2.125

Compatibility Study between Physiologically Based Pharmacokinetic (PBPK) and Compartmental PK Model Using Lumping Method: Application to the Voriconazole Case  

Ryu, Hyo-jeong (College of Pharmacy, Chungnam National University)
Kang, Won-ho (College of Pharmacy, Chungnam National University)
Chae, Jung-woo (College of Pharmacy, Chungnam National University)
Yun, Hwi-yeol (College of Pharmacy, Chungnam National University)
Publication Information
Korean Journal of Clinical Pharmacy / v.31, no.2, 2021 , pp. 125-135 More about this Journal
Abstract
Background: Generally, pharmacokinetics (PK) models could be stratified into two models. The compartment PK model uses the concept of simple compartmentalization to describe complex bodies, and the physiologically based pharmacokinetic (PBPK) model describes the body using multi-compartment networking. Notwithstanding sharing a theoretical background in both models, there was still a lack of knowledge to enhance compatibility in both models. Objective: This study aimed to evaluate the compatibility among PBPK, lumping model and compartment PK model with voriconazole PK case study. Methods: The number of compartments and blood flow on each tissue in the PBPK model were modified using the lumping method, considering physiological similarities. The concentration-time profiles and area under the concentration-time curve (AUC) parameters were simulated at each model, assuming taken voriconazole oral 400 mg single dose. After that, those mentioned PK parameters were compared. Results: The PK profiles and parameters of voriconazole in the three models were similar that proves their compatibility. The AUC of central compartment in the PBPK and lumping model was within a 2-fold range compared to those in the 2- compartment model. The AUC of non-eliminating tissues compartment in the PBPK model was similar to those in the lumping model. Conclusion: Regarding the compatibility of the three PK models, the utilization of the lumping method was confirmed by suggesting its reliable PK parameters with PBPK and compartment PK models. Further case studies are recommended to confirm our findings.
Keywords
Physiologically based pharmacokinetic (PBPK) model; lumping model; compartmental PK model; voriconazole;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012;56(5): 2371-7.   DOI
2 Shin NY, Park MH, Shin YG. Application of physiologically based pharmacokinetic (PBPK) modeling in prediction of pediatric pharmacokinetics. Yakhak Hoeji 2015;59(1):29-39.   DOI
3 Qi F, Zhu L, Li N, Ge T, Xu G, Liao S. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents 2017;49(4):403-9.   DOI
4 Li M, Zhu L, Chen L, Li N, Qi F. Assessment of drug-drug interactions between voriconazole and glucocorticoids. J Chemother 2018;30(5):296-303.   DOI
5 Zhang Y, Zhao S, Wang C, Zhou P, Zhai S. Application of a physiologically based pharmacokinetic model to characterize timedependent metabolism of voriconazole in children and support dose optimization. Front Pharmacol 2021;12:636097.   DOI
6 Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012;55(8): 1080-7.   DOI
7 Chu HY, Jain R, Xie H, et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis 2013;13(1):105.   DOI
8 Sandherr M, Maschmeyer G. Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature. Eur J Med Res 2011;16(4): 139-44.   DOI
9 Ahmed TA. Pharmacokinetics of drugs following IV bolus, IV infusion, and oral administration, In; Basic pharmacokinetic concepts and some clinical applications, London: IntechOpen, 2015: 53-5.
10 International Commission on Radiological Protection. Basic anatomical and physiological data for use in radiological protection: reference values 2002. Available from https://journals.sagepub.com/doi/pdf/10.1177/ANIB_32_3-4. Accessed January 10, 2021.
11 Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. mechanism-based prediction of volume of distribution. J Pharm Sci 2002;91(1):129-56.   DOI
12 Li X, Frechen S, Moj D, et al. A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug-drug interactions. Clin Pharmacokinet 2020; 59(6):781-808.   DOI
13 Elmokadem A, Riggs MM, Baron KT. Quantitative systems pharmacology and physiologically-based pharmacokinetic modeling with mrgsolve: a hands-on tutorial. CPT Pharmacometrics Syst Pharmacol 2019;8(12):883-93.   DOI
14 Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin Jr DK, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and Flavin-containing monooxygenase 3. Drug Metab Dispos 2010; 38(1):25-31.   DOI
15 Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 2012;56(6):3032-42.   DOI
16 Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45(7): 649-63.   DOI
17 Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53(1):24-34.   DOI
18 Sinha VK, Snoeys J, Osselaer NV, Peer AV, Mackie C, Heald D. From preclinical to human-prediction of oral absorption and drugdrug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm Drug Dispos 2012;33(2):111-21.   DOI
19 Chen Y, Jin JY, Mukadam S, Malhi V, Kenny JY. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm Drug Dispos 2012;33(2):85-98.   DOI
20 Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006;45(5):511-42.   DOI
21 Nestorov IA, Aarons LJ, Arundel PA, Rowland M. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokin Biopharm 1998;26(1):21-46.   DOI
22 Pilari S, Huisinga W. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. J Pharmacokinet Pharmacodyn 2010;37(4):365-405.   DOI
23 Zane NR, Thakker DR. A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children. Clin Pharmacokinet 2014;53(12):1171-82.   DOI
24 Anderson ME. Physiologically based pharmacokinetic (PB-PK) models in the study of the disposition and biological effects of xenobiotics and drugs. Toxicol Lett 1995;82-83:341-8.   DOI
25 Liu P, Mould DR. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosos. Antimicrob Agents Chemother 2014;58(8):4718-26.   DOI
26 Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007;34(3):401-31.   DOI
27 Muto C, Shoji S, Tomono Y, Liu P. Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects. Antimicrob Agents Chemother 2015;59(6):3216-23.   DOI
28 Lee JE, Kim SL, Kim YJ, Kim HS, Kim JY. Analysis of dose changing pattern for voriconazole and recommendation. J Kor Soc Health-syst Pharm 2018;35(3):292-309.   DOI
29 Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 2012; 39(6):711-23.   DOI
30 Peters SA, Hultin L. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn 2008;35(1):1-30.   DOI
31 Jones H, Rowland, YK. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol 2013;2(8):1-12.
32 Luu KT, Kraynov E, Kuang B, Vicini P, Zhong WZ. Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies. AAPS J 2013;15(2):551-8.   DOI
33 Lin Z, Gehring R, Mochel JP, Lave T, Riviere JE. Mathematical modeling and simulation in animal health-Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment. J Vet Pharmacol Ther 2016;39(5):421-38.   DOI
34 Southwood R, Fleming VH, Huckaby G. Two-compartment models, In: Concepts in clinical pharmacokinetics, 7th ed, Maryland: American Society of Health-System Pharmacists Inc., 2018: 81-7.
35 Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51(1):45-73.   DOI
36 Teorell T. Kinetics of distribution of substances administered to the body. Arch Intern Pharmacodyn Ther 1937;57:205-25.
37 Urso R, Blardi P, Giorgi G. A short introduction to pharmacokinetics. Eur Rev Med Pharmacol Sci 2002;6(2-3):33-44.
38 Aarons L. Physiologically based pharmacokinetic modelling: a sound mechanistic is needed. Br J Clin Pharmaccol 2005;60(6):581-3.   DOI
39 Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate pharmacokinetics. J Pharm Sci 1971;60(8):1128-33.   DOI
40 Bernareggi A, Rowland ML. Physiologic modeling of cyclosporine kinetics in rat and man. J Pharmacokin Biopharm 1991;19(1):21-50.   DOI
41 Okino MS, Mavrovouniotis ML. Simplification of mathematical models of chemical reaction systems. Chem Rev 1998;98(2):391-408.   DOI
42 Charnick SB, Kawai R, Nedelman JR, Lemaire M, Niederberger W, Sato H. Physiologically based pharmacokinetic modeling as a tool for drug development. J Pharmacokin Biopharm 1995;23(2):217-29.   DOI
43 Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327-60.   DOI
44 Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J Med Res 2014;139(2):195-204.
45 Kang WH, Hwang JA, Chae JW, Kwon KI, Yun HY. The role change of drug metabolism and pharmacokinetics research in the drug development. Yakhak Hoeji 2019;63(3):121-30.   DOI
46 Khojastech SC, Wong H, Hop CECA. Pharmacokinetics, In: Drug metabolism and pharmacokinetics quick guide, New York: Springer, 2011: 8-11.
47 Sager JK, Kishorkumar BB, Ashok MK, Genesh RS, Aruna RR. Solubility and dissolution rate enhancement of antifungal voriconazole by hot melt extrusion and development of sustained release tablets. World J Pharma Res 2014;3(4):1827-53.
48 Khalil F, Laer S. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol 2011;2011:1-13.   DOI
49 US Food and Drug Administration. Guidance for Industry: In Vitro Drug Interaction Studies-Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions 2020. Available from http://www.fda.gov/media/134582/download. Accessed January 10, 2021.
50 Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharma Sci 1983;72(10): 1103-27.   DOI